RT Journal Article
T1 Diet and BMI Correlate with Metabolite Patterns Associated with Aggressive Prostate Cancer.
A1 Grenville, Zoe S
A1 Noor, Urwah
A1 His, Mathilde
A1 Viallon, Vivian
A1 Rinaldi, Sabina
A1 Aglago, Elom K
A1 Amiano, Pilar
A1 Brunkwall, Louise
A1 Chirlaque, María Dolores
A1 Drake, Isabel
A1 Eichelmann, Fabian
A1 Freisling, Heinz
A1 Grioni, Sara
A1 Heath, Alicia K
A1 Kaaks, Rudolf
A1 Katzke, Verena
A1 Mayén-Chacon, Ana-Lucia
A1 Milani, Lorenzo
A1 Moreno-Iribas, Conchi
A1 Pala, Valeria
A1 Olsen, Anja
A1 Sanchez-Perez, Maria-Jose
A1 Schulze, Matthias B
A1 Tjønneland, Anne
A1 Tsilidis, Konstantinos K
A1 Weiderpass, Elisabete
A1 Winkvist, Anna
A1 Zamora-Ros, Raul
A1 Key, Timothy J
A1 Smith-Byrne, Karl
A1 Travis, Ruth C
A1 Schmidt, Julie A
K1 cross-sectional
K1 diet
K1 metabolites
K1 prostate cancer
AB Three metabolite patterns have previously shown prospective inverse associations with the risk of aggressive prostate cancer within the European Prospective Investigation into Cancer and Nutrition (EPIC). Here, we investigated dietary and lifestyle correlates of these three prostate cancer-related metabolite patterns, which included: 64 phosphatidylcholines and three hydroxysphingomyelins (Pattern 1), acylcarnitines C18:1 and C18:2, glutamate, ornithine, and taurine (Pattern 2), and 8 lysophosphatidylcholines (Pattern 3). In a two-stage cross-sectional discovery (n = 2524) and validation (n = 518) design containing 3042 men free of cancer in EPIC, we estimated the associations of 24 dietary and lifestyle variables with each pattern and the contributing individual metabolites. Associations statistically significant after both correction for multiple testing (False Discovery Rate = 0.05) in the discovery set and at p
PB MDPI AG
YR 2022
FD 2022-08-10
LK http://hdl.handle.net/10668/21494
UL http://hdl.handle.net/10668/21494
LA en
NO Grenville ZS, Noor U, His M, Viallon V, Rinaldi S, Aglago EK, Amiano P, et al.Diet and BMI Correlate with Metabolite Patterns Associated with Aggressive Prostate Cancer. Nutrients. 2022 Aug 12;14(16):3306.
NO : This work was supported by Cancer Research UK [C8221/A30904 and C8221/A29017].The coordination of EPIC is financially supported by International Agency for Research on Cancer(IARC) and also by the Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, which has additional infrastructure support provided by the NIHR ImperialBiomedical Research Centre (BRC). The national cohorts are supported by Danish Cancer Society(Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’EducationNationale, Institut National de la Santé et de la Recherche Médicale (INSERM) (France); GermanCancer Aid, German Cancer Research Center (DKFZ), German Institute of Human Nutrition PotsdamRehbruecke (DIfE), Federal Ministry of Education and Research (BMBF) (Germany); AssociazioneItaliana per la Ricerca sul Cancro-AIRC-Italy, Compagnia di SanPaolo and National Research Council(Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), LK Research Funds, DutchPrevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF)(The Netherlands); Health Research Fund (FIS)—Instituto de Salud Carlos III (ISCIII), RegionalGovernments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and the Catalan Instituteof Oncology—ICO (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); and Cancer Research UK (14136 to EPIC-Norfolk (DOI10.22025/2019.10.105.00004); C8221/A29017 to EPIC-Oxford), Medical Research Council (1000143,MR/N003284/1, MC-UU_12015/1 and MC_UU_00006/1 to EPIC-Norfolk; MR/M012190/1 to EPICOxford) (UK). The funders were not involved in designing the study; collecting, analyzing, orinterpreting the data; or writing or submitting the manuscript for publication.
DS RISalud
RD Jul 6, 2025